Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goflikicept Open-Label Extension in Colchicine-Resistant FMF
NCT05190991Phase 2Recruiting
- Sponsor
- R-Pharm
- Start
- Oct 2021
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of goflikicept in Familial Mediterranean fever (FMF), sponsored by R-Pharm. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (AEs) up to 62 weeks, Incidence of Treatment-Emergent Serious Adverse Events (SAEs) up to 62 weeks and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
goflikicept
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT05190991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190991.